Our target clinical application is Dry Age-related Macular Degeneration (Dry AMD).

Our technology has been shown to improve blood flow, reduce inflammation and promote growth of nerve cells ("neurogenesis"). Although the cause of Dry AMD is not known, it is thought that a lack of blood supply to the retina is a major factor in the progression of the disease.

We are currently preparing for clinical studies to test our technology as a potential treatment for Dry AMD, for which there is currently no approved treatment.